Citations

Clear

186 citation(s) found for "Frantz, R".

Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type‐5 inhibitors
Frantz, Robert P. , Hill, Jerrold, Lickert, Cassandra A., Wade, Rolin L. , Cole, Michele, Tsang, Yuen, Drake, William, Frantz, Robert P , Drake, William

Mayo Clinic

Pulmonary Circulation | September 16, 2019 | Volume: 10 | Issue: 1 | Pages: 1-11

10.1177/2045894019880086 | PMID 32274010 Get It

Adherence to therapy for pulmonary arterial hypertension is essential to optimize patient outcomes, but data on real‐world adherence to different pulmonary arterial hypertension drug classes are limited. This retrospective database analysis evaluated relationships between adherence, hospitalization, and healthcare costs in pulmonary arterial hypertension patients treated with endothelin receptor antagonists or phosphodiesterase type‐5 inhibitors. From the IQVIA Adjudicated Health Plan Database, patients with pulmonary arterial hypertension were identified based on diagnostic codes and prescriptions for endothelin receptor antagonists (ambrisentan, bosentan, macitentan) or phosphodiesterase type‐5 inhibitors (sildenafil, tadalafil) approved for pulmonary arterial hypertension. Patients were assigned to the class of their most recently initiated (index) pulmonary arterial hypertension therapy between 1 January 2009 and 30 June 2015. Medication adherence was measured by proportion of days covered; patients with proportion of days covered ≥80% were considered adherent. The proportion of adherent patients was higher for endothelin receptor antagonists (571/755; 75.6%) than for phosphodiesterase type‐5 inhibitors (970/1578; 61.5%; P < 0.0001). In both groups, hospitalizations declined as proportion of days covered increased. Among adherent patients, those on endothelin receptor antagonists had a significantly lower hospitalization rate than those on phosphodiesterase type‐5 inhibitors (23.1% versus 28.5%, P = 0. 0218), fewer hospitalizations (mean (standard deviation) 0.4 (0.8) versus 0.5 (0.9); P = 0.02), and mean hospitalization costs during the six‐month post‐index ($9510 versus $15,726, P = 0.0318). Increasing adherence reduced hospitalization risk more for endothelin receptor antagonists than for phosphodiesterase type‐5 inhibitors (hazard ratio 0.176 versus 0.549, P = 0.001). Rates and numbers of rehospitalizations within 30 days post‐discharge were similar between groups. Mean total costs were higher with endothelin receptor antagonists than phosphodiesterase type‐5 inhibitors in all patients ($91,328 versus $72,401, P = 0.0003) and in adherent patients ($88,867 versus $56,300, P < 0.0001), driven by higher drug costs.
Long‐term results of the DelIVery for Pulmonary Arterial Hypertension trial
Shapiro, Shelley, Tarver, James, Zwicke, Dianne, Feldman, Jeremy P., Chakinala, Murali M. , Frantz, Robert P. , Torres, Fernando , Bag, Remzi , Murphy, Jeffrey A. , Lautenbach, Amy A. , Morris, Marty , Peterson, Leigh , Frantz, Robert P , Gomberg‐Maitland, Mardi , Bourge, Robert C. , Waxman, Aaron B.

Mayo Clinic

Pulmonary Circulation | September 9, 2019 | Volume: 9 | Issue: 4 | Pages: 1-9

10.1177/2045894019878615 | PMID 31723407 Get It

BackgroundThe DelIVery for Pulmonary Arterial Hypertension clinical trial was a multi‐center, prospective, single arm, Investigational Device Exemption study utilizing a fully implantable, programmable intravascular delivery system consisting of a pump and a catheter for intravenous treprostinil. The study met its primary endpoint and demonstrated that the intravascular delivery system significantly reduced catheter related complications at 22,000 subject‐days of follow‐up compared with a predefined objective performance criterion. Here we summarize the results obtained during a 6.4‐year follow‐up period.MethodsThroughout study follow‐up, participants had clinic visits and medication refills at least every 12 weeks (dependent on the subjects’ dose). All adverse events and intravascular delivery system complications were evaluated and recorded.ResultsSixty pulmonary arterial hypertension subjects were followed post device implantation for approximately 282 patient‐years (range 87 days to 6.4 years). Of the 60 subjects, 14 died (1 related to intravascular delivery system pump failure), 2 withdrew after lung transplants, and 2 withdrew due to pump pocket infection. No catheter‐related bloodstream infections, catheter thrombosis or occlusions, or catheter kinks occurred through 282 patient‐years. Two participants had adverse events of abdominal pain, rash, due to subcutaneous treprostinil “leaks” after one catheter puncture and one catheter laceration during pump refill and replacement, respectively. Eight pump failure events occurred: seven pump motor stalls and one early replacement (faulty battery).ConclusionDelivery of treprostinil with an intravascular delivery system is a safe alternative to an external delivery system, while providing enhanced life experiences. To preserve the risk–benefit ratio, treatment at specialized pulmonary arterial hypertension centers is recommended until training is disseminated at other sites.
Intersecting Identities and Patient Outcomes in Pulmonary Arterial Hypertension: Early Results in Derivation of a Model Using the Pulmonary Hypertension Association Registry (PHAR)
Grinnan, D. , Kang, Le , DeWilde, Christine , Johnson, D. , Allen, Roblee P., Badesch, David B., Bartolome, Sonja, Bull, T.M., Chakinala, Murali M. , DeMarco, Teresa , Elwing, Jean , Feldman, Jeremy P., Ford, H. James , Klinger, James R. , Mathai, S.C. , McConnell, J.W. , Presberg, Kenneth W., Ramani, Gautam , Robinson, Jeffrey C. , Runo, James , Sager, Jeffrey S., Shlobin, Oksana A. , Zamanian, R.T., Benza, Raymond L. , Burger, Charles D. , Frantz, Robert P. , Hemnes, Anna R. , Horn, Evelyn M. , Lammi, Matthew R. , Rosenzweig, Erika B. , Simon, Marc A. , Thenappan, Thenappan , Ventetuolo, Corey E. , Williamson, Timothy L.

Mayo Clinic

C52. USE YOUR ILLUSION II: CLINICAL RESEARCH IN PAH | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5098-A5098

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5098 Get It

Diastolic Pulmonary Gradient as a Predictor of Right Ventricular Failure After Left Ventricular Assist Device Implantation
Alnsasra, Hilmi , Schettle, Sarah , Pereira, Naveen L. , Frantz, Robert P. , Edwards, Brooks S., Clavell, Alfredo L. , Maltais, Simon, Daly, Richard C. , Stulak, John M., Rosenbaum, Andrew , Behfar, Atta , Kushwaha, Sudhir S. , Asleh, Rabea , Schettle, Sarah D., Rosenbaum, Andrew N , Behfar, Atta , Frantz, Robert P

Mayo Clinic

Journal of the American Heart Association | August 14, 2019 | Volume: 8 | Issue: 16 | Pages: No page available

10.1161/jaha.119.012073 | PMID 31411097 Get It

Background Diastolic pulmonary gradient ( DPG ) was proposed as a better marker of pulmonary vascular remodeling compared with pulmonary vascular resistance ( PVR ) and transpulmonary gradient ( TPG ). The prognostic significance of DPG in patients requiring a left ventricular assist device ( LVAD ) remains unclear. We sought to investigate whether pre‐ LVAD DPG is a predictor of survival or right ventricular ( RV ) failure post‐ LVAD . Methods and Results We retrospectively reviewed 268 patients who underwent right heart catheterization before LVAD implantation from 2007 to 2017 and had pulmonary hypertension because of left heart disease. Patients were dichotomized using DPG ≥7 mm Hg, PVR ≥3 mm Hg, or TPG ≥12 mm Hg. The associations between these parameters and all‐cause mortality or RV failure post LVAD were assessed with Cox proportional hazards regression and Kaplan–Meier analyses. After a mean follow‐up time of 35 months, elevated DPG was associated with increased risk of RV failure (hazard ratio [ HR ]: 3.30; P =0.004, for DPG ≥7 versus DPG <7), whereas elevated PVR ( HR 1.85, P =0.13 for PVR ≥3 versus PVR <3) or TPG ( HR 1.47, P =0.35, for TPG ≥12 versus TPG <12) were not associated with the development of RV failure. Elevated DPG was not associated with mortality risk ( HR 1.16, P =0.54, for DPG ≥7 versus DPG <7), whereas elevated PVR , but not TPG , was associated with higher mortality risk ( HR 1.55; P =0.026, for PVR ≥3 versus PVR <3). Conclusions Among patients with pulmonary hypertension because of left heart disease requiring LVAD support, elevated DPG was associated with RV failure but not survival, while elevated PVR predicted mortality post LVAD implantation.
Early intervention: should we conduct therapeutic trials for mild pulmonary hypertension before onset of symptoms?
Huston, Jessica , Frantz, Robert P. , Frantz, Robert P , Brittain, Evan L

Mayo Clinic

Pulmonary Circulation | April 1, 2019 | Volume: 9 | Issue: 2 | Pages: 1-8

10.1177/2045894019844994 | PMID 30931829 Get It

Pulmonary arterial hypertension (PAH) is a rare disease that carries a poor prognosis. For 45 years, the definition of pulmonary hypertension (PH) has been a mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg, based on expert opinion. Recent data indicate that the mortality risk starts in the mPAP range of 21–24 mmHg, which has recently been reflected in the World Symposium on PH consensus document defining PH as a mPAP > 20 mmHg. The mortality associated with these lower levels of pulmonary pressures suggests that these values reflect a more advanced disease stage than previously recognized. It is unknown whether interventions targeting patients with mPAP values in the range of 21–24 mmHg in the absence of left ventricular or hypoxic lung disease are of clinical benefit. Here we present historical perspective on the hemodynamic definition of PH, discuss recent epidemiologic data, and outline obstacles to enrolling and evaluating response to therapy in mild PAH patients, as well as potentially useful study designs.
PH Grand Rounds: Puzzling Etiology of Pulmonary Hypertension Resolved
Levine, Deborah J. , Fenstad, Eric R. , Bick, Benjamin L. , Frantz, Robert P.

Mayo Clinic

Advances in Pulmonary Hypertension | February 26, 2019 | Volume: 13 | Issue: 2 | Pages: 65-67

10.21693/1933-088x-13.2.65 Get It

Section editor's note: Welcome to a new section in Advances titled “Pulmonary Hypertension Grand Rounds” (PHGR), which we are introducing in this issue. With this addition, Advances offers a unique opportunity for trainees and junior faculty interested in pulmonary hypertension (PH). This section will highlight cases with literature reviews written by young clinicians and researchers in PH. PHGR was created to use patient cases to integrate individual clinical expertise with the best available evidence from the literature to enable the best decisions for patients. As with the rest of the journal, our audience continues to be physicians, researchers, nurses, students, residents, and fellows interested in both the care of individual patients and the advances in our field. We welcome comments about the section and inquiries regarding submitting a case for publication. Please direct inquiries to advancesgrandrounds@PHAssociation.org
Outcomes After Noncardiac Surgery For Patients With Pulmonary Hypertension: A Historical Cohort Study
Šprung, Juraj , Deljou, Atousa , Sabov, Moldovan, Schroeder, Darrell R. , Johnson, Madeline Q., Sprung, J , Schroeder, Darrell , Kane, Garvan C. , Frantz, Robert P. , DuBrock, Hilary M. , Martin, David, Weingarten, Toby N.

Mayo Clinic

No container title available | February 22, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.391/v1 Get It

Abstract Abstract Background: Pulmonary hypertension (PH) is a significant preoperative risk factor. We aimed to determine predictors of perioperative morbidity and mortality after noncardiac surgery for patients with precapillary PH. Methods: We conducted a retrospective cohort study of adults with pulmonary hypertension having surgery at a single large medical referral center. The PH and surgical databases were reviewed from 2010 to 2017. Patients were excluded if PH was attributable to left-sided heart disease or they had undergone cardiac or transplant operations. To assess whether PH-specific diagnostic or cardiopulmonary testing parameters were predictive of perioperative complications, analyses were performed using generalized estimating equations. Results: Of 196 patients with PH undergoing noncardiac operations, 53 (27%) experienced 1 or more complications, including 5 deaths (3%) within 30 days. After adjustment for age and PH type, there were more complications in those undergoing moderate-to-high vs low-risk procedures (odds ratio [OR], 4.17 [95% CI, 2.07 to 8.40]; P<0.001). After adjustment for age, surgical risk, and PH type, the risk for complications was higher for patients with worse functional status (OR, 2.39 [95% CI, 1.19 to 4.78]; P=0.01 for class 3/4 vs class 1/2) and elevated serum N-terminal fragment of the prohormone brain natriuretic peptide (NT-proBNP) (OR, 2.28 [95% CI, 1.05 to 4.96]; P=0.04 for ≥300 vs. <300 pg/mL). From an analysis that included covariates for age, surgical risk, and functional status, elevated serum NT-proBNP levels remained associated with increased risk (OR, 2.23 [95% CI, 1.05 to 4.76]; P=0.04). Conclusions: Patients with PH undergoing noncardiac surgery with general anesthesia have a high frequency of perioperative complications. Specific clinical (functional status), diagnostic (serum NT-proBNP), and intraoperative factors (higher-risk surgery) are predictive of worse outcomes.
Novel Left Heart Catheterization Ramp Protocol to Guide Hemodynamic Optimization in Patients Supported With Left Ventricular Assist Device Therapy
Rosenbaum, Andrew , Frantz, Robert P. , Kushwaha, Sudhir S. , Stulak, John M., Maltais, Simon, Behfar, Atta , Rosenbaum, Andrew N , Behfar, Atta , Frantz, Robert P

Mayo Clinic

Journal of the American Heart Association | February 13, 2019 | Volume: 8 | Issue: 4 | Pages: No page available

10.1161/jaha.118.010232 | PMID 30755070 Get It

Background Left ventricular (LV) hemodynamic assessment has been sparsely performed in patients supported on continuous‐flow LV assist devices (cf LVADs ). Insight into dynamic changes of left heart parameters during ramp studies may improve LV assist device optimization and evaluate pathology. Methods and Results To complement right heart catheterization, a novel technique for left heart catheterization in patients with a cf LVAD was developed. Patients implanted with cf LVAD s underwent hemodynamic ramp left heart catheterization and right heart catheterization with transthoracic echocardiography. Continuous aortic and LV pressures were measured along with right atrial, pulmonary artery, and pulmonary capillary wedge pressures. A novel index, the transaortic gradient ( TAG ) was established. Thirty eight patients with cf LVADs were evaluated at a median of 446 days (interquartile range, 183–742) after device implant. During left heart catheterization performed for hemodynamic optimization, drop‐in LV end‐diastolic pressure and pulmonary capillary wedge pressure were associated with a rise in TAG . A range was identified for TAG (20–40 mm Hg) as providing the most optimal level of hemodynamic offloading. Pathologic states deviated from normal responses to ramp. LV assist device thrombosis was associated with an inability to increase in TAG during speed ramp. Significant aortic insufficiency was associated with a marked increase in LV end‐diastolic pressure despite a concomitant decrease in pulmonary capillary wedge pressure with increasing LV assist device speeds. Conclusions Inclusion of left heart catheterization to a typical right heart catheterization LV assist device ramp protocol imparted unique insights to optimize cf LVAD speeds in different clinical scenarios. A novel index, the TAG was defined and provided additional resolution to optimized offloading.